The global acute coronary syndrome market is expected to witness significant growth over the forecast period, driven by the rising prevalence of lifestyle-associated disorders such as diabetes, rising cholesterol levels, and obesity. Furthermore, rising incidences of hypertension, growing adoption of drugs, and smoking abuse are likely to trigger market growth in the coming seven years. A shifting lifestyle complemented by changing food habits is one of the prime reasons for the growth of the acute coronary syndrome (ACS) market. ACS is a medical condition resulting due to a reduction in blood flow in the arteries. In this condition, heart muscles are not able to function properly and if not treated at the early stage then it may result in a heart attack. Supportive medical reimbursement facilities, rising personal disposable income, and improving healthcare infrastructure are likely to propel the ACS market growth over the forecast period. In developed nations incidences of ACS are higher than in developing nations, but the mortality associated with ACS in developing nations is higher than in developed economies. Early-stage disease diagnosis and affordable medical treatments can be a possible reasons for low mortality in developed nations.
The ACS market is segmented on the basis of drugs and types. The global acute coronary syndrome market is studied under three main types namely; ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). When the body suffers from a shortage of blood flow and oxygen the chances of unstable angina occurrence increase, which may lead to a heart attack. NSTEMI generally occurs when the coronary artery is partially blocked by blood clots. STEMI occurs when the coronary artery is fully blocked by a clot which may result in the death of the patient. By drugs, the market is segmented into the antithrombotic, antihypertensive, and statin drugs market. Antihypertensive drugs are anticipated to show lucrative growth over the forecast period owing to increasing incidences of high blood pressure, myocardial infarction, and stroke.
Geographically, the global ACS market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA. In 2014, North America and Europe were the dominant regions. Due to rising awareness about acute coronary syndrome the U.S. was the largest market in North America followed by Canada. Asia Pacific region is anticipated to show the highest growth rate over the forecast period owing to the increasing number of outsourcing in the region. Furthermore, increasing disposable income, rising medical tourism, and growing awareness about ACS are expected to drive the market over the forecast period.
The major market players are Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Boehringer Ingelheim, Johnsons & Johnsons, Merck, Novartis, Amgen, AbbVie, Portal Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Eli Lilly, Daiichi, Sanofi, Regeneron, and Sankyo. Due to the presence of a large number of market players, the global acute coronary syndrome market is highly competitive in nature. The firms have to go through many business development activities such as new product development, mergers, collaboration, and geographical expansion to sustain themselves in the market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.